Personalized Glucokinase Activator System for Renal Impairment

A next-generation glucokinase activator system integrating AI-powered dosing algorithms, real-time biomarker analysis, and personalized nutrition planning for optimal treatment outcomes in renally impaired subjects with diabetes.

The original patent disclosed a method for treating glucokinase-mediated disorders in renally impaired subjects using glucokinase activators. However, this approach has limitations in terms of individualized treatment and real-time monitoring. The new inventive concept addresses these limitations by envisioning a comprehensive system that dynamically adjusts treatment regimens based on patient-specific health data and biomarker analysis.

The system comprises a glucokinase activator, an AI-powered dosing algorithm, and a real-time biomarker analysis module. The dosing algorithm receives input from the biomarker analysis module and patient-specific health data, adjusting treatment regimens accordingly. Additionally, the system includes a wearable device for monitoring glucokinase activator efficacy and a personalized nutrition planning module that generates customized meal plans based on individual nutritional needs and health goals. The closed-loop glucokinase activator delivery system ensures optimal dosing regimens in response to real-time glucose level feedback.

The new claims introduce a paradigm shift in glucokinase activator treatment by integrating AI-powered dosing algorithms, real-time biomarker analysis, and personalized nutrition planning. This integration enables dynamic adjustment of treatment regimens, overcoming the limitations of traditional glucokinase activator therapy.

Alternative embodiments may include variations in the AI-powered dosing algorithm, such as incorporating machine learning models or natural language processing. Other variations may include different wearable device designs or personalized nutrition planning approaches. Additionally, the system could be adapted for use in other disease areas or patient populations.

The personalized glucokinase activator system has significant commercial potential in the diabetes management market, particularly in the growing segment of renally impaired subjects. The system's ability to provide optimal treatment outcomes and improve patient quality of life positions it for strong market adoption and potential partnerships with pharmaceutical companies, medical device manufacturers, and healthcare providers.